Clinical analysis of low dose thalidomide combined with conventional chemotherapy in the treatment of multiple myeloma

Objective: To investigate the clinical efficacy and adverse reactions of low dose thalidomide combined with chemotherapy in the treatment of multiple myeloma(MM).Methods: Twenty-six patients with MM were divided into the observation group and control group according to the treatment method(13 cases each group).The control group were treated with conventional chemotherapy,and the observation group were treated with conventional chemotherapy combined with low dose thalidomide.The treatment effect,adverse reaction and prognosis between two groups were compared.Results: The effective rates in observation group and control group were 84.62% and 46.15%,respectively,the difference of which was statistically significant(P<0.05).The thrombocytopenia,leucopenia,mild rash,drowsiness,constipation and other symptoms in some cases were identified after treatment,which were partially relieved after treatment.The incidence rates of adverse reactions in observation group and control group were 38.46% and 46.15%,respectively,the difference of which was not statistically significant(P>0.05).The progression-free survival(PFS) and overall survival(OS) in observation group and control group were(5.6±1.3) & (11.6±2.5) months and (3.8±0.9) & (8.4±1.2) months,respectively.The PFS and OS in observation group were significantly longer than those in control group(P<0.01).Conclusions: The low dose thalidomide combined with conventional chemotherapy after treatment multiple myeloma is good effect and less adverse reaction,which can effectively prolong the survival of patients,and is worthy of promotion and application.